



Advanced Diagnostic  
Laboratories

IMPORTANT NOTICE:

RE New Test Announcement: SC5b-9 Level - Terminal Complement Complex (Urine) - SC59U

Dear Valued Client:

The Advanced Diagnostic Laboratories (ADx) at National Jewish Health is pleased to announce that urine is now an approved sample type for the quantification of soluble C5b-9 protein complex (SC5b-9). This new test offering, available under test code SC59U, allows for quantitative measurement of terminal complement activation in the urine of patients with renal diseases.

Complement mediated renal diseases such as C3 glomerulopathy (C3G), atypical hemolytic uremic syndrome (aHUS), lupus nephritis (LN) and immunoglobulin A nephropathy (IgAN) are characterized by dysregulated complement activation and increased complement activation products, including SC5b-9. Evaluation of SC5b-9 in urine allows providers to assess and monitor terminal complement activation without venipuncture. Additionally, a recent [study](#) has shown that SC5b-9 measured in urine is more sensitive/specific compared to plasma in adults with aHUS.

If you have any questions about this exciting new test or any of our available test offerings, please contact our Client Services Team at 800.550.6227 or via email at [ClinRefLabs@NJHealth.org](mailto:ClinRefLabs@NJHealth.org).

Sincerely,

A handwritten signature in blue ink, appearing to read "Steve Groshong".

Steve Groshong, MD, PhD

Medical Director, Advanced Diagnostic Laboratories

National Jewish Health

---

[njlabs.org](http://njlabs.org) | 800.550.6227 (toll-free) | 800.652.9556 (fax)

[Unsubscribe](#) from emails from this list.



Advanced Diagnostic  
Laboratories

IMPORTANT NOTICE:

RE New Test Announcement : SC5b-9 Level - Terminal Complement Complex (Urine) - SC59U

Dear Valued Client:

The Advanced Diagnostic Laboratories (ADx) at National Jewish Health is pleased to announce that urine is now an approved sample type for the quantification of soluble C5b-9 protein complex (SC5b-9). This new test offering, available under test code SC59U, allows for quantitative measurement of terminal complement activation in the urine of patients with renal diseases.

Complement mediated renal diseases such as C3 glomerulopathy (C3G), atypical hemolytic uremic syndrome (aHUS), lupus nephritis (LN) and immunoglobulin A nephropathy (IgAN) are characterized by dysregulated complement activation and increased complement activation products, including SC5b-9. Evaluation of SC5b-9 in urine allows providers to assess and monitor terminal complement activation without venipuncture. Additionally, a recent [study](#) has shown that SC5b-9 measured in urine is more sensitive/specific compared to plasma in adults with aHUS.

If you have any questions about this exciting new test or any of our available test offerings, please contact our Client Services Team at 800.550.6227 or via email at [ClinRefLabs@NJHealth.org](mailto:ClinRefLabs@NJHealth.org).

Sincerely,

A handwritten signature in blue ink, appearing to read "Steve Groshong".

Steve Groshong, MD, PhD

Medical Director, Advanced Diagnostic Laboratories

National Jewish Health

---

[njlabs.org](http://njlabs.org) | 800.550.6227 (toll-free) | 800.652.9556 (fax)

[Unsubscribe](#) from emails from this list.

